Internal tandem duplication in Fms-like tyrosine kinase 3 (FLT3-ITD) is the most frequent mutation observed in acute myeloid leukemia (AML) and correlates with poor prognosis. FLT3 tyrosine kinase inhibitors are promising for targeted therapy. Here. we investigated mechanisms dampening the response to the FLT3 inhibitor quizartinib. https://fitnessgravesyardes.shop/product-category/tv-connect/